Phase I trial of intravenous AFN 1720, the pro-drug of AFN 1252.

Trial Profile

Phase I trial of intravenous AFN 1720, the pro-drug of AFN 1252.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2015

At a glance

  • Drugs Debio 1450 (Primary)
  • Indications Bacterial infections; Staphylococcal infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 12 Nov 2013 Results are expected in the next few weeks, according to an Affinium Pharmaceuticals media release.
    • 12 Nov 2013 Status changed from recruiting to active, no longer recruiting, as reported by an Affinium Pharmaceuticals media release.
    • 12 Sep 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top